LENZ Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	19.09	-	-	-	-
Cost of Revenue	0.42	-	-	-	-
Gross Profit	18.67	-	-	-	-
Selling, General & Admin	91.14	28.81	12.93	32.85	22.51
Research & Development	18.67	29.8	59.5	72.79	37.93
Total Operating Expenses	109.81	58.61	72.43	105.64	60.44
Operating Income	-91.14	-58.61	-72.43	-105.64	-60.44
Interest Income	9.76	8.55	2.19	4.59	0.02
Other Non-Operating Income (Expense)	-0.24	0.29	0.09	-	-10.34
Total Non-Operating Income (Expense)	9.51	8.84	2.28	4.59	-10.32
Pretax Income	-81.63	-49.77	-70.15	-101.05	-70.76
Provision for Income Taxes	0.5	0	-0.18	-	-
Net Income	-82.13	-49.77	-69.97	-101.05	-70.76
Net Income to Common	-82.13	-49.77	-69.97	-101.05	-70.76
Shares Outstanding (Basic)	29	21	4	4	4
Shares Outstanding (Diluted)	29	21	4	4	4
Shares Change (YoY)	35.39%	415.11%	-	-	1166.12%
EPS (Basic)	-2.85	-2.34	-35.71	-24.46	-17.15
EPS (Diluted)	-2.85	-2.34	-35.71	-24.46	-17.15
Shares Outstanding	31.29	27.52	1.97	8.32	8.29
Free Cash Flow	-70	-59.86	-60.41	-94.57	-58.59
Free Cash Flow Per Share	-2.43	-2.81	-14.62	-22.89	-14.18
Gross Margin	97.81%	-	-	-	-
Operating Margin	-477.46%	-	-	-	-
Profit Margin	-430.25%	-	-	-	-
FCF Margin	-366.71%	-	-	-	-
EBITDA	-90.85	-58.55	-72.41	-103.29	-59.71
EBITDA Margin	-475.96%	-	-	-	-
EBIT	-91.14	-58.61	-72.43	-105.64	-60.44
EBIT Margin	-477.46%	-	-	-	-
Effective Tax Rate	-0.62%	-0.00%	0.26%	0.00%	0.00%

Updated Mar 24, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q